Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer
N. Thatcher et al., Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer, BR J CANC, 80(3-4), 1999, pp. 396-402
Anaemia commonly occurs in cancer patients receiving chemotherapy, often ne
cessitating blood transfusion. This multicentre study was designed to evalu
ate the efficacy and safety of epoetin a in preventing the decline in haemo
globin (Hb) level, and to determine whether the transfusion requirement cou
ld be reduced, in patients receiving 4-6 cycles of primarily platinum-based
combination cyclic chemotherapy for small cell lung cancer (SCLC). A total
of 130 non-anaemic SCLC patients were randomized to receive no additional
treatment (n = 44), epoetin alpha 150 IU kg(-1) subcutaneously (s.c.) three
times a week (n = 42) or 300 IU kg(-1) s.c. three times a week (n = 44)..
Reductions in epoetin alpha dosage were made during the study if Hb level i
ncreased to >15 g dl(-1). The mean weekly dosage was 335 and 612 IU kg(-1),
respectively, in the two active treatment groups. Significantly fewer (P <
0.05) epoetin or-treated patients experienced anaemia (Hb < 10 g dl(-1)) d
uring the course of chemotherapy (300 IU kg(-1), 39%; 150 IU kg(-1), 48%; u
ntreated, 66%). This was reflected in the significantly lower number of tre
ated patients transfused [300 IU kg(-1), 20% (P < 0.001); 150 IU kg(-1), 45
% (P < 0.05); untreated, 59%]. Epoetin alpha was well-tolerated, and there
was no evidence of sustained, clinically significant, hypertension. In summ
ary, epoetin a is effective and well-tolerated in maintaining Hb level and
reducing transfusion requirement in patients undergoing cyclic chemotherapy
for SCLC.